Objective:

To develop a predictive risk model based on mismatch repair (MMR)-associated genes and validate its clinical relevance in glioma patients.

Approach:

Key Findings:

• A prognostic model based on eight MMR-related genes (HMGB1, MCM8, MUTYH, PMS1, RNASEH2B, RNASEH2C, RPA3, TP73) was developed, serving as an independent prognostic indicator.
• High-risk patients exhibited significantly lower overall survival.
• The model's robustness was confirmed using the CGGA dataset.
• Distinct immune infiltration and TMB scores were observed across risk categories.
• MCM8 overexpression increased glioma cell sensitivity to TMZ, while depletion reduced it.

Interpretation:

The study establishes a comprehensive MMR-associated prognostic framework for glioma.

Limitations:

• The study primarily relies on retrospective data from TCGA and CGGA.
• Further validation in diverse cohorts is necessary to confirm findings.

Conclusion:

The research provides a novel MMR-associated prognostic model for glioma and highlights MCM8 as a targetable biomarker influencing TMZ responsiveness.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.